Strategic Investment Advisors MI Decreases Stake in Danaher Co. (NYSE:DHR)

Strategic Investment Advisors MI cut its position in Danaher Co. (NYSE:DHR) by 5.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,410 shares of the conglomerate’s stock after selling 89 shares during the period. Strategic Investment Advisors MI’s holdings in Danaher were worth $324,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of DHR. Decker Retirement Planning Inc. purchased a new position in Danaher in the fourth quarter valued at $31,000. Teachers Insurance & Annuity Association of America purchased a new position in shares of Danaher in the 3rd quarter valued at about $39,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of Danaher during the 3rd quarter worth about $40,000. FSA Wealth Management LLC purchased a new stake in Danaher during the third quarter worth approximately $50,000. Finally, Darwin Wealth Management LLC acquired a new position in Danaher in the third quarter valued at approximately $55,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Performance

Shares of DHR stock opened at $250.51 on Tuesday. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher Co. has a 12-month low of $225.42 and a 12-month high of $281.70. The company has a market cap of $180.94 billion, a price-to-earnings ratio of 47.81, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. The stock has a 50 day simple moving average of $235.33 and a 200-day simple moving average of $253.62.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. Danaher’s payout ratio is currently 20.61%.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Raymond James reduced their price objective on shares of Danaher from $300.00 to $275.00 and set an “outperform” rating for the company in a research report on Tuesday, January 21st. Citigroup decreased their price objective on shares of Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Royal Bank of Canada cut their target price on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Scotiabank assumed coverage on Danaher in a research report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price for the company. Finally, Stephens reaffirmed an “overweight” rating and set a $315.00 price target on shares of Danaher in a research report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $285.55.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.